There’s a key factor limiting the power of a potential Democratic surge next year: the number of seats that are realistically competitive. Even as this year’s election results have left many in the ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Abstract: Observations made using antenna arrays are often limited by the noise coming from the antenna system itself and from the environment. In demanding applications such as radio astronomy, the ...

Investors want to see the math add up and are questioning how much premium they're willing to pay for the promise of future returns. While D-Wave isn't an AI stock per se, it has become caught up in ...

Wave Life Sciences Ltd. (NASDAQ: WVE) on Monday shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE ...

Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, with 4% fat reduction after three months, beating Novo Nordisk’s ...

Wave Life Sciences Ltd. remains a high-risk, high-reward biotech with a unique RNA-based pipeline targeting AATD, obesity, DMD, and Huntington's Disease. I maintain a speculative Buy rating, driven by ...

Abstract: This article presents a dual-port leaky-wave array antenna integrated beam-steerable Schottky heterodyne receiver that may be attractive for terahertz (THz) sensing applications. The ...